Sorry, had to go to "The Crutch"
1. Leronlimab Inducing PD-L1 (On Tumor Cells)
Target/Location: Primarily induced on circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAMLs).
Mechanism: Leronlimab blocks CCR5, which normally suppresses glycosylated PD-L1. By inhibiting CCR5, leronlimab increases total PD-L1 on the surface of tumor cells.
Clinical Significance: This "turns cold tumors hot" by making them more visible to the immune system. This, in turn, makes the tumor more responsive to PD-L1 checkpoint inhibitors. In studies, 88% of patients showed increased PD-L1 after treatment.
2. Leronlimab Inducing PD-1 (On T-Cells)
Target/Location: Induced on T-lymphocytes (specifically CD4+ and CD8+ T cells).
Mechanism: While high PD-1 often signifies "exhausted" T cells, in this context, the increase in PD-1 is associated with a decrease in other exhaustion markers (LAG3, TIM3, CTLA4).
Clinical Significance: The increase in PD-1, combined with the reduction of other, more terminal exhaustion markers, suggests a reactivation of T-cell signaling rather than terminal exhaustion.
Key Differences and Combined Effect
Different Targets: PD-L1 is upregulated on the cancer cell (target), while PD-1 is upregulated on the effector T cell.
Function: Increased PD-L1 acts as a "target" for drugs, while increased PD-1 represents a re-invigorated immune system, according to Rhesus monkey models.
Synergy: Together, leronlimab-mediated induction of both markers works to prime the tumor microenvironment to be more susceptible to immune checkpoint inhibitors (ICIs).
In summary, leronlimab acts as an immune modulator that increases the target for anti-PD-L1 drugs on the cancer cell, while simultaneously reducing exhaustion markers and upregulating PD-1 on T-cells to reactivate them
1. Leronlimab Inducing PD-L1 (On Tumor Cells)
Target/Location: Primarily induced on circulating tumor cells (CTCs) and cancer-associated macrophage-like cells (CAMLs).
Mechanism: Leronlimab blocks CCR5, which normally suppresses glycosylated PD-L1. By inhibiting CCR5, leronlimab increases total PD-L1 on the surface of tumor cells.
Clinical Significance: This "turns cold tumors hot" by making them more visible to the immune system. This, in turn, makes the tumor more responsive to PD-L1 checkpoint inhibitors. In studies, 88% of patients showed increased PD-L1 after treatment.
2. Leronlimab Inducing PD-1 (On T-Cells)
Target/Location: Induced on T-lymphocytes (specifically CD4+ and CD8+ T cells).
Mechanism: While high PD-1 often signifies "exhausted" T cells, in this context, the increase in PD-1 is associated with a decrease in other exhaustion markers (LAG3, TIM3, CTLA4).
Clinical Significance: The increase in PD-1, combined with the reduction of other, more terminal exhaustion markers, suggests a reactivation of T-cell signaling rather than terminal exhaustion.
Key Differences and Combined Effect
Different Targets: PD-L1 is upregulated on the cancer cell (target), while PD-1 is upregulated on the effector T cell.
Function: Increased PD-L1 acts as a "target" for drugs, while increased PD-1 represents a re-invigorated immune system, according to Rhesus monkey models.
Synergy: Together, leronlimab-mediated induction of both markers works to prime the tumor microenvironment to be more susceptible to immune checkpoint inhibitors (ICIs).
In summary, leronlimab acts as an immune modulator that increases the target for anti-PD-L1 drugs on the cancer cell, while simultaneously reducing exhaustion markers and upregulating PD-1 on T-cells to reactivate them
11
